Psilocybin as a new way for depression treatment
DOI:
https://doi.org/10.12775/JEHS.2024.68.50168Keywords
psilocybin, depressionAbstract
Introduction: Mental disorders are common and still growing problem around the globe. Significantly decreasing quality of life, they are often source of true suffering for patients and their families leading to further health issues or even dramatic outcomes resulting in death. As public awareness rises, more and more people understand risks and tend to look for help as fast as possible. Currently available treatment methods are not always efficient enough to deal with more complex cases. Therefore it is important to look for new therapy options incrementing chances of fast and successful treatment.
Results: Studies showed that psilocybin is not only able to lower depression and anxiety scores in patients with major depressive disorders or with serious life-threatening conditions but also proved this effect to be long-lasting. At the same time, no or little adverse side effects were noticed.
Conclusions: Psilocybin is potentially a good method for depression treatment in some groups of patients. It should be considered if other, better known therapies show little or no effects.
References
Mental disorders [Internet]. [cited 2022 Sep 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/mental-disorders
Roser M, Ritchie H. Burden of Disease. Our World in Data. 2021 Sep 25;
Prevalence by mental and substance use disorder, World, 2019 [Internet]. [cited 2022 Sep 18]. Available from: https://ourworldindata.org/grapher/prevalence-by-mental-and-substance-use-disorder?time=latest
Zhou Y, Rosenheck R, Mohamed S, Ou Y, Ning Y, He H. Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China. BMC Psychiatry [Internet]. 2016 Aug 11 [cited 2024 Mar 19];16(1). Available from: /pmc/articles/PMC4980784/
Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry [Internet]. 2014 Oct 1 [cited 2024 Apr 1];1(5):343–50. Available from: https://pubmed.ncbi.nlm.nih.gov/26360998/
Tsaras K, Papathanasiou I V., Mitsi D, Veneti A, Kelesi M, Zyga S, et al. Assessment of Depression and Anxiety in Breast Cancer Patients: Prevalence and Associated Factors. Asian Pac J Cancer Prev [Internet]. 2018 Jun 1 [cited 2024 Apr 1];19(6):1661. Available from: /pmc/articles/PMC6103579/
Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017 Jan 15;372:331–41.
Siegmann EM, Müller HHO, Luecke C, Philipsen A, Kornhuber J, Grömer TW. Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis. JAMA Psychiatry [Internet]. 2018 Jun 1 [cited 2024 Apr 1];75(6):577. Available from: /pmc/articles/PMC6137529/
Pandarakalam JP. Challenges of Treatment-resistant Depression. Psychiatr Danub [Internet]. 2018 [cited 2024 Apr 1];30(3):273–84. Available from: https://pubmed.ncbi.nlm.nih.gov/30267518/
Nuñez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord [Internet]. 2022 Apr 1 [cited 2024 Apr 1];302:385–400. Available from: https://pubmed.ncbi.nlm.nih.gov/34986373/
Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019 May 1;197:83–102.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The Therapeutic Potential of Psilocybin. Molecules 2021, Vol 26, Page 2948 [Internet]. 2021 May 15 [cited 2024 Apr 1];26(10):2948. Available from: https://www.mdpi.com/1420-3049/26/10/2948/htm
Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addiction Biology. 2002 Oct;7(4):357–64.
Coppola M, Bevione F, Mondola R. Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective? J Xenobiot [Internet]. 2022 Mar 1 [cited 2024 Apr 2];12(1):41. Available from: /pmc/articles/PMC8883979/
Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, et al. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs 2021 36:1 [Internet]. 2021 Nov 17 [cited 2024 Mar 5];36(1):17–30. Available from: https://link.springer.com/article/10.1007/s40263-021-00877-y
Goel DB, Zilate S. Potential Therapeutic Effects of Psilocybin: A Systematic Review. Cureus [Internet]. 2022 Oct 12 [cited 2024 Apr 2];14(10). Available from: /pmc/articles/PMC9650681/
Tylš F, Páleníček T, Horáček J. Psilocybin - Summary of knowledge and new perspectives. European Neuropsychopharmacology. 2014 Mar;24(3):342–56.
Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction [Internet]. 2004 Jun 1 [cited 2024 Apr 1];99(6):686–96. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1360-0443.2004.00744.x
Leary T, Litwin GH, Metzner R. Reactions to psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease. 1963;137(6):561–73.
Timothy L, Ralph M, Madison P, Gunther W, Ralph S, Sara K. A new behavior change program using psilocybin. Psychotherapy: Theory, Research & Practice [Internet]. 1965 [cited 2022 Sep 22];2(2):61–72. Available from: /doiLanding?doi=10.1037%2Fh0088612
Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016 Jul 1;3(7):619–27.
Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018 Feb 1;235(2):399–408.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine [Internet]. 2022 Nov 3 [cited 2024 Mar 6];387(18):1637–48. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2206443
Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology [Internet]. 2023 Sep 1 [cited 2024 Mar 6];48(10):1492. Available from: /pmc/articles/PMC10425429/
Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA [Internet]. 2023 Sep 5 [cited 2024 Mar 6];330(9):843–53. Available from: https://jamanetwork.com/journals/jama/fullarticle/2808950
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021 May 1;78(5):481–9.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology. 2016 Dec 1;30(12):1181–97.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology. 2016 Dec 1;30(12):1165–80.
Agrawal M, Richards W, Beaussant Y, Shnayder S, Ameli R, Roddy K, et al. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. 2023;
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. 2021 Apr 15;384(15):1402–11.
Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology [Internet]. 2022 Feb 1 [cited 2024 Mar 6];36(2):151–8. Available from: https://journals.sagepub.com/doi/full/10.1177/02698811211073759?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mateusz Maciej Pawlicki, Aleksandra Kłos, Karol Stachyrak, Dawid Mika, Bartosz Mazur, Kamila Turek, Maciej Lambach, Anna Greguła, Aleksandra Mazurek, Wiktoria Wilanowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 203
Number of citations: 0